Physician

Dexter T Estrada, M.D.

According to 2025 Medicare claims, Dexter Estrada, M.D. (NPI: 1013032713) practices hematology/oncology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Estrada's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,232 traditional Medicare patients, billed 487,212 HCPCS/CPT codes, and received $7,007,159 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,616 prescription claims across 383 beneficiaries totaling $5,647,293 in drug costs, led by Ibrance (Palbociclib). DME data shows 229 claims. Open Payments data shows 74 records totaling $1,601. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $3,676,675 to $7,007,159. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,320,660 to $5,647,293. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,691 and ending at $2,807.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,026	454,266	$3,676,675
2016	795	442,991	$3,387,671
2017	789	519,412	$3,494,652
2018	780	386,430	$3,441,181
2019	800	364,753	$3,463,801
2020	1,064	522,735	$5,204,066
2021	1,100	611,221	$6,993,274
2022	1,048	546,274	$6,700,726
2023	1,292	622,149	$7,692,273
2024	1,232	487,212	$7,007,159

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	188	1,377	$1,320,660
2016	213	1,740	$2,409,773
2017	233	1,869	$2,587,729
2018	241	1,785	$2,722,372
2019	254	1,822	$2,642,151
2020	274	2,026	$3,443,325
2021	281	2,249	$4,376,804
2022	317	2,432	$4,645,629
2023	331	2,324	$5,018,954
2024	383	2,616	$5,647,293

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	107	$37,552
2016	N/R	46	$11,994
2017	N/R	92	$34,787
2018	N/R	194	$95,346
2019	N/R	266	$84,727
2020	N/R	138	$44,681
2021	N/R	66	$6,729
2022	N/R	224	$60,755
2023	N/R	132	$12,317
2024	N/R	229	$65,222

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	664	1,597	$98
96372	Injection of drug or substance under skin or into muscle	396	1,451	$11
80053	Blood test, comprehensive group of blood chemicals	558	1,877	$10
36415	Insertion of needle into vein for collection of blood sample	688	2,632	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	693	2,698	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	88	2,450	$1,249,500
Lenalidomide	Lenalidomide	43	1,206	$825,527
Cabometyx	Cabozantinib S-Malate	23	690	$564,602
Pomalyst	Pomalidomide	20	560	$456,963
Revlimid	Lenalidomide	14	392	$265,495

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4197	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, 74 to 100 grams of protein - premix	N	N/R	22	$47,526
B4185	Parenteral nutrition solution, not otherwise specified, 10 grams lipids	N	N/R	34	$6,299
B4224	Parenteral nutrition administration kit, per day	N	N/R	34	$6,165
B4220	Parenteral nutrition supply kit; premix, per day	N	N/R	34	$1,974
J8521	Capecitabine, oral, 500 mg	N	N/R	24	$930

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	74	$1,601	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dexter T. Estrada, M.D.?

Tedicare shows public-source Medicare data for Dexter T. Estrada, M.D. (NPI 1013032713), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dexter T. Estrada, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Dexter T. Estrada, M.D.?

Dexter T. Estrada, M.D. is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Dexter T. Estrada, M.D. have Open Payments data?

Dexter T. Estrada, M.D. has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.